In NSCLC, PD-L1 inhibitors (atezolizumab, durvalumab) were primarily associated with thyroiditis or hypophysitis (10–16%), whereas anti-PD-1 agents showed higher rates of CIADM (11–13%), adrenal insufficiency (10–12%), and thyroid dysfunction (30–38%). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.